# OnCo record paper-davis-bmj (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-davis-bmj/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-davis-bmj" ;
  schema:name "Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: retrospective cohort study of drug approvals 2009-13"@en ;
  schema:description "Paper cited by two bottleneck pages and 15 idea pages, indexed on Europe PMC as PubMed record 28978555 and published in BMJ; the citing pages link this DOI, which is how the record was matched."@en ;
  schema:url <https://onco.cc/key-papers/paper-davis-bmj/> ;
  schema:dateModified "2026-09-22"^^xsd:date ;
  schema:citation <https://doi.org/10.1136/bmj.j4530>, <https://pubmed.ncbi.nlm.nih.gov/28978555/>, <https://europepmc.org/article/MED/28978555> ;
  onco:tag "europepmc-ingest" ;
  schema:sameAs <https://doi.org/10.1136/bmj.j4530> ;
  schema:datePublished "2017"^^xsd:gYear ;
  schema:author "Davis C, Naci H, Gurpinar E, et al." ;
  onco:related <https://onco.cc/bottlenecks/b-toxicity-qol/>, <https://onco.cc/bottlenecks/b-trial-design/>, <https://onco.cc/ideas/idea-tr1-window-of-opportunity-default/>, <https://onco.cc/ideas/idea-tr1-tumour-agnostic-approval-standard/>, <https://onco.cc/ideas/idea-tr1-aggregated-n-of-1-supportive-care/>, <https://onco.cc/ideas/idea-tr1-ai-central-imaging-reads/>, <https://onco.cc/ideas/idea-tr1-shrinkage-subgroup-analysis/>, <https://onco.cc/ideas/idea-tr1-shared-control-arms-across-sponsors/>, <https://onco.cc/ideas/idea-tr1-target-trial-emulation-to-prioritise-rcts/>, <https://onco.cc/ideas/idea-tr1-crossover-adjusted-survival-standard/>, <https://onco.cc/ideas/idea-tr1-immunotherapy-stop-trials/>, <https://onco.cc/ideas/idea-tr1-randomised-phase-2-before-phase-3/>, <https://onco.cc/ideas/idea-tr1-seamless-2-3-with-prespecified-go/>, <https://onco.cc/ideas/idea-tr1-smart-designs-for-adaptive-strategies/>, <https://onco.cc/ideas/idea-tr1-aggressive-futility-boundaries/>, <https://onco.cc/ideas/idea-tr1-ctdna-guided-stop-in-metastatic-disease/>, <https://onco.cc/ideas/idea-tr1-validate-real-world-progression-endpoints/> ;
  onco:journals <https://onco.cc/journals/bmj/> .